Cardiovascular effects of sodium–glucose cotransporter 2 inhibitors: multiple actions

Current Medical Research and Opinion

Volumn 32, Issue 9, 2016, Pages 1513-1514

  Katsiki, Niki ^a   Athyros, Vasilios G ^b   Mikhailidis, Dimitri P ^c  

^a Hippocration Hospital ^*  (Greece)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE; SODIUM; SODIUM GLUCOSE COTRANSPORTER 2;

ARTERIAL STIFFNESS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DRUG MECHANISM; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; WEIGHT CONTROL;

DIABETES MELLITUS, TYPE 2; GLUCOSE; HYPOGLYCEMIC AGENTS; SODIUM; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84978488310     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1201465     Document Type: Letter

References (19)

1. P.Lefebvre, D.Pilon, M.N.Robitaille,. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin – an electronic health-record-based study. Curr Med Res Opin 2016;32:1151-9
2. M.J.Davies, A.Trujillo, U.Vijapurkar,. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015;17:426-9
3. S.E.Inzucchi, B.Zinman, C.Wanner,. SGLT-2 inhibitors and cardiovascular risk:proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015;12:90-100
4. N.Katsiki, A.Karagiannis, V.G.Athyros, D.P.Mikhailidis. Hyperuricaemia:more than just a cause of gout? J Cardiovasc Med (Hagerstown) 2013;14:397-402
5. L.De Nicola, F.B.Gabbai, M.E.Liberti,. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy:targeting the renal tubule in diabetes. Am J Kidney Dis 2014;64:16-24
6. R.K.Ghosh, D.Bandyopadhyay, A.Hajra,. Cardiovascular outcomes of sodium–glucose cotransporter 2 inhibitors:a comprehensive review of clinical and preclinical studies. Int J Cardiol 2016;212:29-36
7. V.G.Athyros, N.Katsiki, A.Karagiannis. Can glucagon like peptide 1 (GLP1) agonists or sodium–glucose co-transporter 2 (SGLT2) inhibitors ameliorate non-alcoholic steatohepatitis in people with or without diabetes? Curr Vasc Pharmacol 2016 In press
8. V.G.Athyros, K.Tziomalos, N.Katsiki,. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease:an update. World J Gastroenterol 2015;21:6820-34
9. E.Lioudaki, M.Florentin, E.S.Ganotakis, D.P.Mikhailidis. Microalbuminuria:a neglected cardiovascular risk factor in non-diabetic individuals? Curr Pharm Des 2013;19:4964-80
10. K.Riggs, H.Ali, H.Taegtmeyer, A.D.Gutierrez. The use of SGLT-2 inhibitors in type 2 diabetes and heart failure. Metab Syndr Relat Disord 2015;13:292-7
11. H.Yanai, H.Katsuyama, H.Hamasaki,. Sodium–glucose cotransporter 2 inhibitors:possible anti-atherosclerotic effects beyond glucose lowering. J Clin Med Res 2016;8:10-14
12. A.Tahara, E.Kurosaki, M.Yokono,. Effects of sodium–glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol 2014;66:975-87
13. M.C.Michel, E.Mayoux, V.Vallon. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn Schmiedebergs Arch Pharmacol 2015;388:801-16
14. C.V.Desouza, N.Gupta, A.Patel. Cardiometabolic effects of a new class of antidiabetic agents. Clin Ther 2015;37:1178-94
15. D.P.Mikhailidis, M.Elisaf, M.Rizzo,. European panel on low density lipoprotein (LDL) subclasses:a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011;9:533-71
16. A.Otocka-Kmiecik, D.P.Mikhailidis, S.J.Nicholls,. Dysfunctional HDL:a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314-24
17. B.Zinman, J.M.Lachin, S.E.Inzucchi. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2016;374:1094
18. C.Sonesson, P.A.Johansson, E.Johnsson, I.Gause-Nilsson. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories:a meta-analysis. Cardiovasc Diabetol 2016;15:37
19. M.Monami, C.Nardini, E.Mannucci. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes:a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:457-66